20 closest matches · ranked by relevance
MERS (Middle East Respiratory Syndrome)
Primary: Percentage of Participants Experiencing Solicited Local or Systemic Reactogenicity as Defined by the Study Protocol — 10; 10 Participants
Middle East Respiratory Syndrome Coronavirus
Primary: Number of Participants Having Adverse Events — 1; 2; 2; 4 Participants
Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
Primary: Part 1: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs), Graded by Severity, and Treatment-related AEs — 34.4; 30.3; 43.8; 31.3 percentage of…
Sars-CoV2 · Acute Respiratory Distress Syndrome · COVID-19
Primary: Proportion of Participants With Treatment-related Serious Adverse Events (tSAEs) — 0; 0 proportion of participant
Acute Respiratory Distress Syndrome
Primary: Incidence of Pre-specified Infusion Associated Adverse Events — 0; 0; 0 participants
Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (Disorder)
Primary: Number of Participants With Treatment-emergent Adverse Events as Assessed by Protocol Definition of AE — 3; 0; 0; 1 Participants
Respiratory Distress Syndrome, Adult
Primary: Change in Oxygenation Index (OI) — -0.7; -1.5; 0.8; -1.1 cmH20/mmHg — p=0.34
Healthy
Primary: Change From Baseline in Self-Reported Symptom Scores From Well-to-Sick State Through Day 56 — 0.065; 0.281; 0.036; 0.113 Scores on a scale — p=<.0001
SARS-CoV-2 Acute Respiratory Disease · Covid19
Primary: Number of Participants With Normal and Above Triage (STC-19) Score — 52; 12; 4; 5 Participants
Respiratory Tract Infection
Primary: Percentage of Participants With a Fast Recovery — 12.8; 54.3; 27.4; 29.7 percentage of participants
Respiratory Syncytial Virus
Primary: Panel A vs Panel C: Peak Viral Load (PVL) Determined by Viral Quantitative Culture — 2.55; 2.84 log10 plaque forming units (PFU)/mL — p=0.578
Viral Respiratory Infection
Primary: Time to Resolution of Acute Respiratory Viral Infection (ARVI) Symptoms — 4.1; 5.0 days — p=0.0155
Respiratory Distress Syndrome, Adult
Primary: Numbers of Patients Occurred Pre-specified Infusion Associated Events Occurring Within 6 Hours of Study Infusion — 0; 0 Participants
COVID-19 Pneumonia, Impaired Respiratory Function
Primary: APACHE II Severity of Disease Score on Day 15 or on the Day of Discharge (Whichever is Earlier) — 14.5; 13.5 Score on a scale — p=0.33
Covid19 · SARS-CoV-2 PNEUMONIA · COVID-19
Primary: Number of Participants With Non-serious and Serious Adverse Events During Trial — 0; 0; 0; 0 Participants
Respiratory Syncytial Virus Infections · Respiratory Viral Infections
Primary: Host Response to RSV Challenge Measured as Change From Baseline of Chemical Mediators in Nasal Fluid — 23 Participants
COVID
Primary: Cohort 1, Phase 2: Percentage of Participants Alive and Free of Mechanical Ventilation at Day 29 — 85.7; 87.5; 74.4 percentage of participants — p=0.2598
Respiratory Syncytial Virus Bronchiolitis
Primary: Percentage of Participants With Asthma at 6 Years of Age: Overall and by Prognostic Factor — 6.1; 11.2; 3.1; 9.6 percentage of participants
Covid19
Primary: Sensitivity of Detecting SARS-CoV-2 RNA — 31; 0 Participants
SARS-CoV-2 Infection
Primary: Number of Patients With TEAEs — 3; 4; 3; 1 Participants